GR3023542T3 - Quinolone carboxylic acid--metal ion--acid complexes - Google Patents

Quinolone carboxylic acid--metal ion--acid complexes

Info

Publication number
GR3023542T3
GR3023542T3 GR970401192T GR970401192T GR3023542T3 GR 3023542 T3 GR3023542 T3 GR 3023542T3 GR 970401192 T GR970401192 T GR 970401192T GR 970401192 T GR970401192 T GR 970401192T GR 3023542 T3 GR3023542 T3 GR 3023542T3
Authority
GR
Greece
Prior art keywords
quinolone carboxylic
metal ion
acid
carboxylic acid
complexes
Prior art date
Application number
GR970401192T
Other languages
English (en)
Inventor
Laman A Al-Razzak
Francisco J Alvarez
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23822659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3023542(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of GR3023542T3 publication Critical patent/GR3023542T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/06—Aluminium compounds
    • C07F5/069—Aluminium compounds without C-aluminium linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR970401192T 1989-12-29 1997-05-23 Quinolone carboxylic acid--metal ion--acid complexes GR3023542T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45892789A 1989-12-29 1989-12-29
PCT/US1990/007584 WO1991009525A1 (en) 1989-12-29 1990-12-20 Quinolone carboxylic acid--metal ion--acid complexes

Publications (1)

Publication Number Publication Date
GR3023542T3 true GR3023542T3 (en) 1997-08-29

Family

ID=23822659

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970401192T GR3023542T3 (en) 1989-12-29 1997-05-23 Quinolone carboxylic acid--metal ion--acid complexes

Country Status (14)

Country Link
US (1) US5334589A (el)
EP (1) EP0507851B1 (el)
JP (1) JP3153549B2 (el)
AT (1) ATE150973T1 (el)
AU (1) AU647772B2 (el)
CA (1) CA2072366C (el)
DE (1) DE69030387T2 (el)
DK (1) DK0507851T3 (el)
ES (1) ES2102393T3 (el)
GR (1) GR3023542T3 (el)
IE (1) IE904725A1 (el)
IL (1) IL96776A (el)
PT (1) PT96400B (el)
WO (1) WO1991009525A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9118183D0 (en) * 1991-08-23 1991-10-09 Solanki Kishor K Imaging of infections
US5290794A (en) * 1992-10-27 1994-03-01 Warner Lambert Co. Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms
US6024979A (en) * 1995-06-06 2000-02-15 Solvay Animal Health, Inc. Oral veterinary composition containing a fluoroquinolone antibacterial agent possessing superior absorption properties and an extended duration of therapeutic antimicrobial blood levels, and a method of treating a microbial infection in a ruminant
JP3416145B2 (ja) * 1995-12-21 2003-06-16 ファイザー インク． 注射用キノロン製剤
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE10018781A1 (de) * 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Infusionslösungen des Ciprofloxacins mit verbesserter Lagerfähigkeit
US20090117205A1 (en) * 2004-07-02 2009-05-07 Daiichi Pharmaceutical Co., Ltd Quinolone-containing medicinal composition
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
WO2016195014A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
CN105524060B (zh) * 2016-03-10 2017-03-22 青岛云天生物技术有限公司 一种制备盐酸莫西沙星的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208470A (en) * 1983-07-18 1988-06-30 Abbott Lab 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.

Also Published As

Publication number Publication date
AU647772B2 (en) 1994-03-31
AU7153191A (en) 1991-07-24
IL96776A0 (en) 1991-09-16
DK0507851T3 (da) 1997-08-25
EP0507851A1 (en) 1992-10-14
IE904725A1 (en) 1991-07-17
PT96400B (pt) 1998-06-30
US5334589A (en) 1994-08-02
DE69030387T2 (de) 1997-10-23
EP0507851B1 (en) 1997-04-02
ES2102393T3 (es) 1997-08-01
PT96400A (pt) 1991-10-15
ATE150973T1 (de) 1997-04-15
JPH05502879A (ja) 1993-05-20
CA2072366A1 (en) 1991-06-30
EP0507851A4 (en) 1993-03-17
DE69030387D1 (de) 1997-05-07
JP3153549B2 (ja) 2001-04-09
CA2072366C (en) 2002-08-20
IL96776A (en) 1997-02-18
WO1991009525A1 (en) 1991-07-11

Similar Documents

Publication Publication Date Title
IL96776A0 (en) Quinolone carboxylic acid-metal ion-acid complexes
MY110734A (en) Improvements in or relating to dioic acids.
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
DE3880587T2 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
HK109395A (en) Pharmaceutical uses of fatty acids
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
GR3001565T3 (en) Medical preparation comprising aspoxicillin, a method for its preparation, and the use of such a preparation for the manufacture of a medicament
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
UA10219A (uk) Спосіб лікування туберкульозу легень
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
UA19647A (uk) Спосіб лікуваhhя остеомієліту щелепи
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
NO930083L (no) Sammensetning for behandling av alzheimers sykdom og fremgangsmaate for fremstilling av samme